15 results about "Tropomyosin" patented technology

This invention relates to drug conjugates useful for localized treatment of diseases or disorders of the middle ear and / or inner ear. Methods of treating diseases or disorders of the middle ear and / or inner ear, pharmaceutical compositions comprising the conjugates, and methods of inhibiting a Tropomyosin receptor kinase are also provided.

The invention relates to the technical field of allergen proteins and antigen epitopes, and discloses an Antarctic krill allergen and an identification method and application of the Antarctic krill allergen, the Antarctic krill allergen and the antigen epitopes are used for identifying the Antarctic krill allergen and the antigen epitopes, and the identification method comprises the steps of Antarctic krill crude protein extraction, Antarctic krill allergen screening and identification. Extracting an antarctic krill map and verifying allergens; analyzing the homology of the euphausia superba and analyzing the conformation of tropomyosin of the euphausia superba; carrying out euphausia superba tropomyosin epitope analysis; and allergens and epitopes of the euphausia superba are applied. According to the invention, the antarctic krill allergen is identified as tropomyosin, eight antigen epitopes of the antarctic krill tropomyosin allergen are ascertained, the stability change rule in the hot working process is analyzed by utilizing the identified antarctic krill allergen and antigen epitopes, and the result shows that the stability of the antarctic krill allergen is greatly improved under the processing condition of 140 DEG C or below. And the conformation of the tropomyosin of the euphausia superba and the binding capacity of the tropomyosin with protein immune globulin E or immune globulin G are kept stable.

This invention belongs to the field of pharmaceutical synthesis technology, specifically relating to a diarylurea derivative, its preparation method, and its application. The diarylurea derivative of this invention is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which exhibits high inhibitory activity against wild-type (WT), mutant G595R, and G667C tropomyosin receptor kinase (TRK), and can be used to treat NTRK fusion-positive locally advanced or metastatic solid tumors.

The invention relates to the technical field of biology, and particularly discloses marine bacterial protease as well as a coding gene, a preparation method and application thereof. The invention provides protease 4SP5-519 capable of specifically degrading allergenic tropomyosin in aquatic products and reducing the sensitization of the allergenic tropomyosin, and the protease 4SP5-519 is applied to improving the food safety of the aquatic products.

Disclosed herein are compounds and pharmaceutical compositions useful for treating, preventing, reducing, or ameliorating diseases or conditions associated with neurodegenerative disorders. Without being bound by theory, the disclosed compounds and compositions are believed to selectively target tropomyosin receptor kinase A (TrkA) receptor-mediated pro-survival signaling pathways or the nerve growth factor (NGF) or the neurosteroid dehydroepiandrosterone (DHEA) and may prevent, treat, reduce, or ameliorate neurodegeneration.

The invention relates to the technical field of food analysis, and provides a method for analyzing the sensitization effect of natural carbohydrate chains on food allergens, which comprises the following steps: extracting and purifying tropomyosin freeze-dried powder in food muscle tissues, identifying the types of carbohydrate chains in the tropomyosin freeze-dried powder, and analyzing the types of glucosidic bonds; removing an N-carbohydrate chain and an O-carbohydrate chain in the tropomyosin freeze-dried powder by using one or more of a PNGase F enzyme removal method, a beta-elimination method and a trifluoromethanesulfonic acid method, so as to obtain a deglycoprotein; a phenol-sulfuric acid method, SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis) and PAS (Polyacrylamide Sulfate) dyeing are used for evaluating the anti An in vitro test and an in vivo test are used to evaluate the effect of the desugaring treatment on the allergenicity of tropomyosin. By analyzing the regulation influence of the natural carbohydrate chain on the allergenicity of the penaeus chinensis tropomyosin, a foundation is laid for deep research on the allergenicity of the penaeus chinensis tropomyosin, and an innovative perspective of analyzing the allergenicity characteristics of the penaeus chinensis tropomyosin is provided.

The present invention is in the field of medicinal chemistry and relates to a novel pyrazolopyridine derivative and its preparation and use as therapeutic agents, in particular as TRK inhibitors. Compounds of general formula (I) and their geometric isomers or pharmaceutically acceptable salts thereof and their preparation. Preferred compounds have activity as protein kinase inhibitors, in particular tropomyosin receptor kinase (TRK) inhibitors.

In some aspects, the disclosure provides antibody-based reagents that specifically bind a tropomyosin receptor kinase B (TrkB) isoform that is associated with cancers. In some embodiments, the isoform is TrkB.T1. In some embodiments, the antibody or antibody derivative specifically binds a polypeptide comprising, consisting essentially of, or consisting of the sequence FVLFHKIPLDG (SEQ ID NO:1), or a sequence with at least 80% sequence identity thereto. In other aspects, the disclosure provides methods of producing the antibody or antibody derivative, related hybridomas, and methods of detecting and treating cancers incorporating use of the disclosed antibody reagents.

This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

Provided herein are proteins that include a Vascular Endothelial Growth Factor A (VEGF-A) protein binding domain; proteins that include an Epstein-Barr Virus BCL-2 homolog (BHRF1) protein binding domain; proteins that include a Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) RBD protein binding domain; proteins that include an Interleukin-7 receptor subunit alpha (IL7R-α) protein binding domain; proteins that include a Programmed death-ligand 1 (PD-L1) protein binding domain; proteins that include a Tropomyosin-receptor kinase A (Trk-A) protein binding domain; and proteins that include an Interleukin-17 (IL-17A) protein binding domain.

The application belongs to the field of pharmaceutical chemistry, and particularly relates to a Tropomyosin Receptor Kinase A (TrkA) inhibitor and a preparation method and application thereof, a structural formula of which is shown as formula (I); the compound provided by the application has high inhibitory activity on TrkA and good subtype selectivity. The compound has potential application in analgesic treatment, including but not limited to chronic pain caused by osteoarthritis, cancer pain, back pain and the like; the compound also has potential anticancer activity.

Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed. The pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5b-]pyridin-2-amine in microcrystalline suspension formulations in its monohydrate form, which shows improved characteristics over the anhydrate form, and in extended release formulations. The extended release pharmaceutical formulations comprise 3-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)-6-(1-methyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridin-2-amine-loaded microspheres.

The invention relates to the technical field of biology. The invention provides a method for reducing allergenicity based on an alpha-dicarbonyl compound modified tropomyosin allergen epitope, which comprises the following steps: analyzing the epitope in tropomyosin, ascertaining a glycosylation modification site in the epitope, and directionally modifying the epitope by adopting the alpha-dicarbonyl compound, so as to reduce the allergenicity of the tropomyosin allergen epitope. Directional resistance and control of allergenicity of tropomyosin are realized, technical support is provided for guaranteeing body health and life quality of aquatic food allergy patients in China, and research and development of low-allergy or non-allergy aquatic food are further promoted.

The invention provides a T cell epitope fusion protein aiming at main allergens of Fujian oysters and application of the T cell epitope fusion protein. The T cell epitope fusion protein comprises four T cell epitopes of allergen tropomyosin (Craa a 1) and two T cell epitopes of allergen arginine kinase (Craa a 2); a KK connexon is used between the epitopes of the same allergen, and the epitopes of different allergens are connected in series by using an EAAAK connexon; the amino acid sequences of the four T cell epitopes of the Cra a 1 are as shown in SEQ ID NO: 1-4, and the amino acid sequences of the two T cell epitopes of the Cra a 2 are as shown in SEQ ID NO: 5-6. The T cell epitope fusion protein solves the problems of high cost of hybrid peptides and limitation of monoallergens in oyster allergy treatment, can be applied to preparation of desensitization preparations, prevention of oyster allergic diseases and reduction of side effects in immunotherapy, and provides a new strategy for development of efficient broad-spectrum oyster allergy oral immunotherapy preparations.